Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

101.76 +0.02 (+0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues ↗

February 23, 2022

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-...

Via Benzinga

4 Big Ark Innovation Components Report Earnings This Week: Could It Spell More Danger For Cathie Wood? ↗

February 23, 2022

The Ark Funds ETFs have been hit hard in 2022 with growth stocks among the laggards as investors turned to value stocks. Many stockholders have begun to question ...

Via Benzinga

Exact Sciences: Q4 Earnings Insights ↗

February 22, 2022

Exact Sciences (NASDAQ:EXAS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For February 22, 2022 ↗

February 22, 2022

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu...

Via Benzinga

A Preview Of Exact Sciences's Earnings ↗

February 21, 2022

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-02-22. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months? ↗

February 17, 2022

Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,...

Via Benzinga

Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer

February 02, 2022

Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...

Via FinancialNewsMedia

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

January 24, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...

Via FinancialNewsMedia

10 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗

January 14, 2022

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...

Via Benzinga

Why Exact Sciences Share Are Falling Today? ↗

January 10, 2022

Exact Sciences Corp (NASDAQ: EXAS) has put down $190 million to buy testing laboratory PreventionGenetics, aiming to expand its diagnostics franchise into...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 06, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell ↗

December 07, 2021

Its positioning in cancer diagnostics is good, but it faces an important headwind.

Via The Motley Fool

Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods

December 01, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the...

Via FinancialNewsMedia

Exact Sciences Breaks Up With Pfizer -- Time to Buy? ↗

December 01, 2021

The end of a co-promotion deal with Pfizer could work out well for Exact Sciences.

Via The Motley Fool

The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout ↗

November 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...

Via Benzinga

Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test ↗

November 30, 2021

Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal...

Via Benzinga

Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought ↗

November 29, 2021

The internet's favorite stock picker has been very busy.

Via The Motley Fool

Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand

November 11, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...

Via FinancialNewsMedia

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021 ↗

November 03, 2021

Upgrades Benchmark upgraded the previous rating for Devon Energy Corp (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

November 03, 2021

Needham boosted Paycom Software, Inc. (NYSE:PAYC) ...

Via Benzinga

25 Stocks Moving in Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to...

Via Benzinga

Exact Sciences Shares Drop After Guiding Lower Screening Revenue For FY21 ↗

November 03, 2021

Exact Sciences Corp's (NASDAQ: EXAS) Q3 revenues rose 12% Y/Y to $456.4 million, beating the consensus of $430.03 million. The increase is attributable to increased...

Via Benzinga

Exact Sciences (EXAS) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

EXAS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Why Exact Sciences' Stock Is Trading Higher Today ↗

September 15, 2021

Exact Sciences (NASDAQ:EXAS) shares are trading higher after the company announced an expansion of its primary care sales team with the addition of former Pfizer sales...

Via Benzinga

3 Crash-Ready Stocks to Buy in September ↗

September 14, 2021

History says this month can be scary. These stocks can get you through it.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.